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Abstract Stroke is the second most common cause of death
worldwide and of adult disability, but in the near future the
global burden of cerebrovascular diseases will rise due to
ageing and adverse lifestyle changes in populations worldwide.
The risk of stroke increases at blood pressure levels above
115/75 mm Hg and high blood pressure (BP) is the most
important modifiable risk factor for stroke, associated with
54 % episodes of stroke worldwide. There is strong evidence
from clinical trials that antihypertensive therapy reduces
substantially the risk of any type of stroke, as well as stroke-
related death and disability. The risk attributed to BP is
associated not only with absolute values but also with certain
parameters describing BP diurnal pattern as well as short-term
and long-term variability. Many studies reported that certain
features of BP like nocturnal hypertension, morning surge or
increased variability predict an increased stroke risk. However,
there is no accepted effective modality for correction of these
disturbances (chronotherapy, certain classes of antihypertensive
drugs). In the elderly, who are mostly affected by stroke, the
primary prevention guidelines recommend treatment with
diuretics and calcium channel blockers to lower blood pressure
to the standard level.
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Introduction
For last three decades, stroke remains the second most
common cause of mortality [1] and recently has become the
third leading cause of global disease burden estimated using
disability-adjusted life years [2]. In developed countries,
despite decreased incidence of stroke, paradoxically the
absolute number of stroke victims still raises because of rapid
ageing of population and tight correlation of stroke risk
with age [3]. These trends are accompanied by a decline of the
mean age of stroke victims, which is now 69 years [4]. On the
contrary, in low income and middle income countries the
incidence of stroke is growing and nowadays two-thirds of all
individuals that have suffered from a stroke live in developing
countries where stroke is the second cause of disabilities. Due
to these trends in global health, cerebrovascular disease is
predicted to remain the second leading cause of mortality,
reaching almost eight million annual deaths by 2030 [5] .
Blood Pressure and the Risk of Stroke
The relationship between hypertension and stroke was first
described by Frederick Akbar Mohamad - a physician of
mixed Indian and Irish origin working in Guy’s Hospital in
London in the 19th century. He constructed a quantitative
sphygmograph to estimate the level of blood pressure and
described a natural history of essential hypertension, including
initial asymptomatic stage, subclinical lesions (left ventricular
hypertrophy) and finally, clinical complications, including
cerebrovascular accidents like transient ischemic attacks
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intensive (aggressive) hypotensive therapy, morning surge, white coat,
blood pressure variability, nondipping, therapy and treatment.
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(“a passing paralysis”) or stroke (“severe apopleptic seizure”)
[6].
In the 20th century, major risk factors for stroke were
identified and their relative impact estimated. Globally, 51 %
of stroke deaths are attributable to high systolic BP and local
rates of incidence of stroke are correlated with the prevalence
of hypertension. Hypertension is the major modifiable factor
and the second most powerful risk factor after age, regardless
of geographic location and ethnic background. Blood pressure
is amajor determinant of both ischemic and hemorrhagic stroke
(intracerebral and subarachnoid) and correlates with the risk of
the first as well as recurrent episodes of cerebrovascular
incidents.
Components of Blood Pressure and the Risk of Stroke
The Framingham Heart Study is the longest-running,
prospective epidemiologic project, initiated in 1948 to identify
potential and reversible causes of cardiovascular diseases.
Although originally the study was designed to analyze causes
of coronary heart disease in men younger than 60 years, after
six decades of research it provided valuable information on the
effects of different factors on the risk of stroke and cognitive
dysfunction.
Results of the first cohort of subjects showed that
hypertensive patients (with BP>160/95 mm Hg) had the
incidence of stroke five to more than 30 times higher as
compared to normotensive persons (<140/90 mm Hg)
depending on age and gender. The increased risk was also
noted in so-called “borderline hypertensives”. Using data [7]
from subjects aged 55-84 years and free of cerebrovascular
disease at the time of data collection, probability of stroke was
calculated. The Framingham stroke prediction algorithm
(http://www.framinghamheartstudy.org/risk/stroke.html)
included SBP values and age, diabetes mellitus, smoking,
history of cardiovascular disease, presence of atrial fibrillation,
left ventricular hypertrophy and the use of hypertensive
medication.
Initial observations from the Framingham study found
casual SBP as good as a predictor of stroke as various
components of BP, including diastolic and mean arterial
pressure, pulse pressure, as well as lability of pressure [8].
Individual data of 958,074 subjects participating in 61
separate prospective studies without known cardiovascular
disease at the baseline were used in the meta-analysis [9] to
calculate correlation between BP and mortality from stroke.
This is the largest meta-analysis ever published, which
was preceded by earlier studies by the same group of authors
including smaller groups of subjects [10, 11]. The results of
Prospective Study Collaboration show that in patients
between 40-89 years of age, BP is strongly and directly
associated with total vascular and stroke mortality. Each
difference of 20 mmHg of systolic and 10 mm of diastolic Hg
was associated with doubling the risk of stroke death. This
correlation was continuous without any evidence of a
threshold down to at least 115/75 mm Hg. For stroke
mortality, average BP was a slightly better predictor than
any components of BP, and systolic BP was more informative
than diastolic BP or pulse pressure (SBP-DBP difference).
The pattern of correlation between BP and stroke mortality
was similar in males and females, any type of stroke and
geographical regions.
Results of the meta-analysis by the Prospective Study
Collaboration are contradictory to some previous findings,
which identified a widened pulse pressure as an independent
marker of cardiovascular risk, including stroke [12]. For
example, analysis of data from the elderly with isolated
systolic hypertension from SHEP (Systolic Hypertension in
the Elderly Program) study demonstrated an 11 % increase in
stroke risk and a 16 % increase in risk of all-cause mortality
for each 10-mm Hg increase in pulse pressure [13]. Since
widened pulse pressure results from increased conduit vessel
stiffness, this association may indicate more advanced lesions
in arteries and other target organs. These findings were
confirmed by meta-analysis of three trials including systolic
hypertension in the elderly (European Working Party on High
Blood Pressure in the Elderly, Systolic Hypertension in
Europe Trial (Syst-Eur), and Systolic Hypertension in China
Trial (Syst-China) [14].
Similarly, in a Finnish study of 4,333 men and 5,270
women aged 45-64 years with no history of vascular disease,
the risk of coronary heart disease, stroke, cardiovascular
disease and all-cause mortality increased with the increasing
pulse pressure during 15 years of follow up, independent of
the DBP level. However, after adjustment for systolic blood
pressure, the positive association between mortality and
increasing pulse pressure disappeared [15].
Results of some studies suggest that an ethnic background
may modify the impact of BP on stroke risk. The Reason for
Geographic And Racial Differences in Stroke (REGARDS)
study included 30,239 black and white individuals over
45 years of age, who were observed for at least 4.5 years.
Among white participants, a difference in SBP of 10 mm Hg
was associated with an 8 % increase in stroke risk; among
black participants, a 10-mmHg difference was associatedwith
a 24 % increase. The black-white disparity was higher in
younger individuals and at a higher SBP level. The results of
the REGARDS study suggest that blacks are more susceptible
to stroke but the difference may be also attributed to higher
prevalence and poorer control of high BP in Afro-Americans
[16].
In eastern Asian countries, stroke was a leading cause of
death with a greater incidence, higher mortality and greater
proportion of hemorrhagic stroke as compared to Western
Europe and North America. The Eastern Stroke and
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Coronary Heart Disease Collaboration Project aimed to
study associations of diastolic BP and cholesterol level with
the cardiovascular risk in populations in China and Japan.
Using data from 124,774 participants the authors suggested
a stronger impact of DBP on stroke risk than in Western
countries [11] . However, they have not confirmed their own
data in the following Prospective Study Collaboration using
global registry (see above).
The majority of studies included in the Prospective Study
Collaboration meta-analysis recorded only stroke-related
mortality, not incidence; also, type of stroke was not identified
in about half of the cases. The INTERSTROKE study
evaluated risk factors for first-time acute stroke in 22 countries
in order to determine major modifiable risk factors [17••]. The
data on 3,000 strokes (78 % ischemic) were collected and
compared with 3,000 matched control cases. Type of stroke
was diagnosed using neuroimaging and hypertension and
was defined either as self-reported or when BP higher than 160/
90 was measured during examination. Five risk factors were
identified that contributed to 80 % of stroke risk: hypertension,
smoking status, waist-to-hip ratio, diet and physical activity.
Hypertension was diagnosed in 55% and 83% of patients with
ischemic and hemorrhagic stroke, respectively, while among
controls there were 37 % subjects with high BP. Five other risk
factors accounted for an additional 10% of stroke risk: diabetes
mellitus, alcohol use, psychosocial factors , cardiac causes and
ratio of apolipoprotein B to apolipoprotein A1. Some other
factor, not analyzed in the INTERSTROKE study, may affect
the risk of cerebrovascular risk. For example, hypertensive
patients with a first-ever episode of stroke had a larger left atrial
size and left ventricular mass index [18].
The results of the INTERSTROKE study showed that
hypertension was the strongest risk factor for all types of
stroke, with the greater risk for intracerebral haemorrhagic
stroke than for ischaemic stroke. The impact of hypertension
was greater in individuals younger than 45 years than in those
aged 45 years or older.
Office and Ambulatory Measurements and the Risk
of Stroke
Due to multiple readings, ambulatory blood pressure
monitoring (ABPM) offers better accuracy of assessment of
a subject’s BP with higher sensitivity and specificity for
diagnosis of hypertension than office-based BPmeasurements
[19]. A number of studies have suggested that the risk of
target-organ damage and cardiovascular complications
correlates more closely with 24-hour, daytime, or nighttime
ABPM than with the office pressure [20]. Moreover,
only ABPM allows for detection of abnormalities in circadian
rhythm of BP like white-coat or masked hypertension,
non-dipping or extreme dipping and morning surge. Results
of ABPM readings can be used to calculate variables, like the
ambulatory arterial stiffness index that can better estimate
target organ lesions and cardiovascular risk [21].
However, prospective studies using ABPM for
cardiovascular risk assessment included relatively small
groups with a limited number of outcome events, frequently
stroke episodes were not reported separately [22]. Conen and
Bamberg made a meta-analysis which included 9,299
participants with 11.1 years of follow up [23] and 881
cardiovascular events. They found a consistent association
between mean 24-h systolic BP and cardiovascular mortality
and morbidity, even after adjustment for office BP. ABPM
was a stronger predictor of stroke than other cardiovascular
events, such as cardiovascular and total mortality. For each
10 mm Hg increase of 24-h SBP , there was a hazard ratio
(95 % confidence interval) of 1.33 (1.22-1.44) for stroke, 1.19
(1.13-1.26) for cardiovascular mortality, 1.12 (1.07-1.17) for
total mortality and 1.17 (1.09-1.25) for cardiac endpoints.
In their meta-analysis , daytime and nighttime BP have a
similar ability to predict cardiovascular events, including
stroke; however, higher nighttime BP was associated with
increased total mortality as well as cardiovascular mortality.
The results of their meta-analysis are confirmed by recent data
from the IDACO study (International database onAmbulatory
blood pressure in relation Cardiovascular Outcomes) which
shows that 24-h systolic BP was a stronger predictor of stroke
than cardiac events and cardiovascular mortality [24].
Unfortunately, there are limited data on 24-h DBP;
therefore, the effect of diastolic values on the risk of stroke
and other cardiovascular complications cannot be estimated.
The Dublin Outcome Study included 5,292 untreated
hypertensive patients who had clinic and ambulatory blood
pressure measurement at baseline, and they were followed for
a median period of 8.4 years [25]. With adjustment for gender,
age, body mass index, smoking status, diabetes, history of
cardiovascular events and clinic BP, higher mean values of
ambulatory blood pressure were independent predictors for
cardiovascular mortality. The relative hazard ratio for each
10-mm Hg increase in systolic blood pressure was 1.12
(1.06 to 1.18; p =0.001) for daytime and 1.21 (1.15 to 1.27;
p =0.001) for nighttime systolic blood pressure. The hazard
ratios for each 5-mm Hg increase in diastolic blood pressure
were 1.02 (0.99 to 1.07; p =NS) for daytime and 1.09 (1.04 to
1.13; p =0.01) for nighttime diastolic pressures. Nighttime
ABPM provided additional predictive information over
daytime ABPM, as does ABPM SBP over ABPM DBP, for
total, cardiovascular, stroke, and cardiac mortality.
In most of these studies, ABPM was recorded in initially
untreated subjects or during a placebo run-in phase. The
Office versus Ambulatory Blood Pressure (OvA) Study
included 1,963 patients without history of cardiovascular
incident who were followed for a median of five years [26].
All subjects had an ABPM recording after at least three
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months of blood pressure lowering treatment and a higher
ambulatory systolic or diastolic blood pressure predicted for
cardiovascular events even after adjustment for classic risk
factors including office measurements of blood pressure. For
cerebrovascular outcomes analyzed separately, ambulatory
blood pressure was not predictive of the risk after adjustment
for office blood pressure. However, office SBP was associated
with stroke risk, and the number of episodes could be too
small (36 patients) to detect a significant association.
Dipping Status and the Risk of Stroke
The average nocturnal BP is approximately 15 percent lower
than daytime values in both control and hypertensive patients.
Based on 24-hour BP monitoring, subjects can be classified as
nondippers (nocturnal reduction of systolic pressure by <10%
of awake systolic pressure), dippers (reduction by ≥10 %
to <20 %), and extreme dippers (reduction by ≥20%). In some
patients so-called “reverse dipping” has been described with an
increase in BP during nighttime [27•]. The dipper/nondipper
classification of nocturnal blood pressure was first introduced
in 1988 when a retrospective analysis suggested that
hypertensive patients without nocturnal fall in BP had a higher
risk of stroke than the majority of patients with a dipping
pattern [28]. Dipping pattern is associated not only with
clinical cerebrovascular events but also with the development
of silent brain infarcts [29]. In asymptomatic hypertensive
patients who underwent 24-hour monitoring and brain
magnetic resonance imaging, the frequency of asymptomatic
cerebrovascular damage (silent infarcts and advanced deep
white matter ischemic lesions) was higher in nondippers as
compared to dippers, and extreme dippers had more advanced
cerebrovascular lesions [30, 31].
Since then, there have been many studies evaluating
morbidity and dipping status, andmost large-scale prospective
studies support the concept that a diminished nocturnal blood
pressure decline is associated with a worse prognosis [32, 33].
Moreover, three longitudinal studies conducted in patients
with hypertension have shown that a diminished nocturnal
decline in blood pressure predicts cardiovascular events
[34–36]. One study suggested that daytime pressure is a better
predictor of cardiac events than nighttime pressure, the latter
being more important for stroke [37].
The first prospective study to demonstrate that a
diminished nocturnal decline in blood pressure is a risk factor
for cardiovascular mortality, independent of the overall blood
pressure load during a 24-hour period, was the Ohasama study
in a Japanese population, which showed that, on average, each
5 % decrease in the decline in nocturnal blood pressure was
associated with 20 % greater risk of cardiovascular mortality.
Importantly, this association was observed not only in
hypertensive individuals but also in normotensive individuals
[38]. Kario et al. [36] prospectively observed group of 575
patients with sustained hypertension and known dipping
status. Baseline brain magnetic resonance imaging (MRI)
disclosed that the percentages with multiple silent cerebral
infarcts were 53 % in extreme-dippers, 29 % in dippers,
41 % in nondippers, and 49 % in reverse-dippers. During
follow up for an average duration of 41 months, they recorded
54 stroke incidents, and there was a J-shaped relationship
between dipping status and stroke incidence (extreme-dippers,
12 %; dippers, 6.1 %; nondippers, 7.6 %; and reverse-dippers,
22 %). Intracranial hemorrhage was more common in reverse-
dippers (29 % of strokes) than in other subgroups (7.7 % of
strokes, p <0.04).
Despite the absolute risk of cardiovascular complications,
the relation to blood pressure is lower in women than in men,
the relation between differences in ABPM values and the rates
of cardiovascular complications – including stroke - is higher.
Data published by the IDACO consortium showed a much
steeper relation of all cardiovascular events and stroke with
nighttime BP. Again, the BP level achieved at night was more
important than the amount of dipping per se. In this study
9,357 subjects (4397 women) were prospectively observed
for the median of 11.2 years and both office and 24-hour
ambulatory BP were recorded [39].
White Coat Hypertension and the Risk of Stroke
In many patients blood pressure taken in the office may be
substantially higher than BP during normal daily activities.
White coat hypertension (WCH), also called isolated clinic or
office hypertension, is diagnosed when BP is elevated in the
office at repeated visits but remains normal out of the office,
either on ABPM or HBPM. The prevalence of WCH ranges
from 10 to more than 20 percent, and appears to be higher in
children and the elderly. Awhite coat hypertension effect may
also occur in patients with apparently resistant hypertension
and is called “white coat reaction”. In a study of nearly 500
treated hypertensive patients (over 60 percent on three or more
antihypertensive agents), 37 % had normal BP onABPM [40].
The prognostic relevance of WCH still remains a matter of
controversy. Cross-sectional studies demonstrated a higher
frequency of target organ damage in patients with WCH
than in normotensive controls [41]. Results of longitudinal
studies show that cardiovascular risk was slightly higher
compared with persistent normotension but well below the
risks associated with either masked or sustained hypertension.
In three prospective cohort analyses including nearly 6,000
subjects followed for a median of 7.5 years, the risk of
stroke was 15 % greater in WCH patients as compared to
normotensive population, but the difference was not statistically
significant [42]. Analysis of subjects withWCHamong patients
with isolated systolic hypertension included in the IDACO
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database show no difference in cardiovascular risk between
normotensive and WCH patients, either treated or untreated.
However, observed risk was significantly higher compared to
patients with masked or sustained hypertension. Stroke
episodes were not analyzed separately [43]. In a recent meta-
analysis which included nearly 8,000 untreated subjects with
WCH diagnosed by means of ABPM, there was no significant
difference in cardiovascular risk between normotensive and
WCH patients [44].
However, a small number of patients included in studies
with short time of follow-up and low initial cardiovascular risk
make an unequivocal demonstration of correlation between
WCH and increased CVrisk difficult. Therefore,WCH cannot
be considered an innocent finding. In the Hisayama Study
2,915 Japanese aged over 40 years had ABPM performed
along with ultrasound screening for carotid atherosclerosis
[45]. As compared to normotensive population, subjects with
WCH had significantly higher intima-media thickness of the
carotid artery (0.73 mm vs. 0.67 mm, p <0.001) and increased
likelihood of carotid stenosis (odds ratio 2.36 with 95 % CI
1.27-4.37).
In long-term studies, the incidence of stroke in WCH
patients began to rise after 6-8 years of observation [42, 44].
Although they have “normal” ABPM or HBPM, still their
values are slightly, yet significantly higher, than BP levels
recorded in normotensive controls [46]. They also show a
greater prevalence and severity of metabolic risk factors and
are characterized with a greater 24-hour BP variability [47].
WCH patients are frequently treated, and the reduction of
clinic BP leads to a reduced incidence of CV events. In the
Hypertension in the Very Elderly Trial [48], treatment of
hypertensive subjects over 80 years of age with indapamide/
perindopril versus matching placebo was associated with a
30 % reduction in the rate of fatal or nonfatal stroke, a 39 %
reduction in the rate of death from stroke as well as lower total
mortality and the risk of other analyzed clinical endpoints
[48]. In a small group of patients from both active treatment
and placebo groups, ABPM was measured and the results
suggest that between 40 % and 60 % of eligible participants
in the main study may have had WCH [49]. Therefore, in
the elderly, WHC may be associated with an increased
cardiovascular risk and active treatment could reduce incidence
of significant clinical complications, including stroke. To
change current clinical practice, appropriate randomized
clinical trials should be required.
Masked Hypertension and the Risk of Stroke
The term “masked hypertension” was introduced by Thomas
Pickering to describe patients who are normotensive by
conventional clinic measurement and hypertensive by
ABPM [50]. This phenomenon, also called isolated
ambulatory hypertension, has been identified by screening
clinical studies, since patients who are normotensive by office
readings do not typically undergo ambulatorymonitoring. The
prevalence of masked hypertension depends on the study
population, setting and modality of out-of-office measurement
(ABPM or home blood pressure monitoring, HBPM). Meta-
analysis which used data from 28 studies including 25,605
subjects found average prevalence of masked hypertension of
16.8% (95%CI13.0-20.5%)[51]. There are two categories of
causal mechanism of masked hypertension: selective
reduction of office BP relative to out-of-office BP attributed
to the “regression to the mean” phenomenon, and the presence
of conditions that selectively increase ambulatory BP. These
factors may include smoking, increased physical activity,
drinking, obesity, anxiety and job stress, male gender and
younger age [20, 51–54]. Poor treatment adherence and intake
of medications immediately before scheduled visit can also be
responsible cause [55].
Patients with masked hypertension have higher left
ventricular mass than normotensives [51, 54, 56]. In The
Hisayama Study, subjects with masked hypertension had
intima-media thickness of the carotid artery similar to sustained
hypertensives (0.77 mm) significantly higher than normotensive
population (0.67 mm, p<0.001), and increased risk of carotid
stenosis (odds ratio 1.95with 95%CI 1.25-3.03) as compared to
control population [45]. These data confirm previous findings
from smaller studies [57, 58]. Masked hypertension is associated
with an increased pulse wave velocity, a measure of arterial
stiffness, similar to sustained hypertensives and significantly
higher than in normotensive subjects [58].
Masked hypertension has been associated with an increased
long-term risk of sustained hypertension and cardiovascular
morbidity similar to stage 1 hypertension. In the latest meta-
analysis including eight studies with 7,961 subjects [51],
compared with normotension, the overall hazard ratio for
cardiovascular events was 2.09 (95%CI 1.55-2.81) for masked
hypertension, 0.96 (95 % CI 0.65-1.42) for WCH and 2.59
(95 % CI 2.9-3.335) for sustained hypertension (p =0.0001).
All these surveys took into account total cardiovascular
complications without separating cerebrovascular events [51,
54, 59].
Because of the risk associated with masked hypertension,
ABPM should be considered in patients referred for possible
hypertension (for a variety of reasons, such as left ventricular
hypertrophy) despite repeatedly normal BP when measured in
the clinic [60].
Morning Surge and the Risk of Stroke
Frequency of cardiovascular complications shows a diurnal
variation with a peak incidence between 6 AM and noon [61].
Systematic review of the data on timing of the onset of acute
Curr Hypertens Rep (2013) 15:559–574 563
stroke and the subtype of stroke was performed using 31
reports including 11,816 strokes [62]. All cerebrovascular
events, ischemic and hemorrhagic stroke as well as transient
ischemic episodes, displayed a significant variation in time of
onset. The time period of the highest risk was found between 6
and 9 AM and the lowest number of events occurred from
midnight to 3 AM. There was a 58 % “morning excess” of
strokes when compared with the value expected if all strokes
had been evenly distributed. Risk of all subtypes of stroke was
increased during morning hours (6 AM to noon): 55 % for
ischemic stroke, 34 % for hemorrhagic stroke and 76 % for
transient ischemic accidents. Diurnal pattern in stroke onset is
independent of patient demographics, clinical features, or
predisposing risk factors [63, 64].
Morning excess of cardiovascular risk parallels the normal
circadian pattern of BP, heart rate, physical activity, plasma
catecholamines, cortisol, and other humoral and nervous factors.
Cerebral blood flow, autoregulation and cerebrovascular
reactivity to physiologic stimuli are impaired in the morning
and that might explain the increased risk of stroke [65]. Also,
increase in sympathetic activity, impaired endothelial function
and increased platelet aggregability could contribute to morning
excess of cardiac and cerebral events [66].
Some studies suggest that circadian system modulates not
only cardiovascular risk markers (i.e., BP or heart rate) at rest
but also their reactivity to environmental factors [67]. In
certain subjects an exaggerated BP response to regular daily
physical activity can be observed and for that phenomenon the
term “morning surge” was coined.
Kario and associates first demonstrated that this phenomenon
is an independent risk factor for cardiovascular diseases,
including stroke. This findings were confirmed in six
prospective studies (for review see [68••]. Subjects with
“morning surge” – even without hypertension, have a higher
incidence of target organ damage (left ventricular hypertrophy,
carotid atherosclerosis, intima-media thickness, pulse wave
velocity), higher levels of inflammatory markers and urinary
catecholamines and albumin excretion [69–71].
Increased stiffness of large arteries results in reduced
sensitivity of carotid baroreceptors. Thus, they cannot initiate
an effective reflex response to suppress BP surge, particularly
in the morning. This notion is supported by a correlation of
baroreflex response during the Valsalva maneuver with an
increase in morning BP [72].
Morning surge is associated with many factors: ageing,
glucose intolerance, alcohol intake, psychological and
physical stress, and sleep apnea [68••]. Increases in BP after
awakening are higher on Mondays and over the winter and
this may explain Monday and winter peak of cardiovascular
incidents [73, 74].
However, only one study investigated the association
between morning surge and the time of onset of acute
cerebrovascular event [75]. The Jichi Medical University
School of Medicine Japan Morning Surge Ambulatory
Blood Pressure Monitoring Study included 519 older
hypertensives with silent cerebral infarct detected on brain
MRI, and who were followed up prospectively for an average
of 41 months. Incidence of stroke episodes in the morning
hours was higher in those with morning surge as compared to
subjects without an exaggerated rise in BP after being awake.
In this study, the morning surge was associated with stroke
events independently of 24-hour BP, nocturnal BP dipping
status, and baseline prevalence of silent infarct (P=0.008).
However, Pierdomenico et al., observing 1,191 elderly treated
for hypertension (mean follow up 9.1±4.9 years) found that
morning surge of systolic BP was not associated with the risk
of stroke in a population as a whole. When dippers and
nondippers were analyzed separately, in dippers stroke risk
was significantly higher in the third tertile (>23 mm Hg of
systolic BP) of morning surge (hazard ratio 2.08 95 % CI
1.03-4.23, p =0.04). Stroke risk was significantly and
similarly higher in dippers with morning surge >23 mm Hg
of systolic BP and in nondippers as compared to the group of
dippers with morning surge<23 mm Hg of systolic BP [76].
Morning surge is detected based on ABPM measurements
and there are some controversies regarding reproducibility of
this phenomenon [77, 78], which may be related to the lack of
uniform definition. Studies defining morning surge as the BP
2-hour after rising (morning BP) minus the average BP during
sleep (sleep BP) provided the most reproducible results.
There are no clinical studies that pharmacological treatment
of morning surge results in regression of target organ damage
and prevention of cardiovascular complications. Bedtime
dosing of antihypertensive medications may reduce morning
rise in BP and it was reported in small open-label studies with
doxazosine (The Japan Morning Surge Study 1) and
candesartan (the Japan-Target Organ Protection Study). Also,
reduction in albumin excretion was observed [79, 80].
However, whether prevention of morning surge as well
as reversal of nondipping is possible or beneficial is uncertain
and this hypothesis should be tested in randomized clinical
trials in the future. Unfortunately, the Controlled Onset
Verapamil Investigation of Cardiovascular End Points
(CONVINCE) trial, which was designed to compare
chronotherapy with standard treatment was stopped
prematurely. However, data available showed that controlled-
onset extended-release verapamil was not better than standard
therapy with beta-blocker and thiazide for preventing coronary
heart disease and stroke [81].
Blood Pressure Variability and the Risk of Stroke
Blood pressure variability (BPV) may be divided into short-
term variability including changes in BP from beat-to-beat or
within 24 hours, midterm-day by day, and long-term
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variability related to BP fluctuations between visits, seasons,
years and even decades [82]. Physiologically, short-term
changes in BP represent an adaptive response of body
regulatory systems to internal and external stimuli. Short-
term BPV, usually expressed as the average of standard
deviation or coefficient of variation of BP readings during
different time intervals, is associated with the risk of
cardiovascular complications but is a much weaker predictor
of future outcomes than the 24-hour ambulatory blood
pressure level [83]. Also, BPV derived from home BP
measurements was not a stronger predictor of cardiovascular
risk than mean systolic BP [84, 85].
Long-term BPV shows only weak correlation with short
term fluctuations (assessed with ABPM) and may result from
different determinants like seasonal changes due to ambient
temperature and daylight hours, errors in BP readings, low
patients’ compliance and adherence, and behavioral changes
related to workdays and weekends [8, 47, 86]. Results from
the twin study suggest that some phenotypes of BPV may be
genetically determined [87].
Both short or long term BPV has been associated with
development, progression and severity of cardiac, vascular
and renal organ damage and with an increased risk of
cardiovascular events and mortality, independently of basic
BP levels (for review see [88••]. For the first time, investigators
of the Swedish Trial in Old Patients with Hypertension (STOP)
observed that active treatment reduced the risk of stroke
more than it could be attributed to the reduction of BP per se
[89]. They suggested that therapy with antihypertensive
medications might protect against stroke by decreasing
variability in BP.
Recently, Rothwell et al. [90] conducted a post hoc analysis
of the data of UK Transient Ischemic Attack aspirin trial
(UK-TIA), selecting a cohort of patients with at least seven
office BPmeasurements, once every four months. They found
substantial BPV within a single subject from one visit to the
next, even when antihypertensive regimen was not changed.
In the UK-TIA trial, visit-to-visit systolic BPV was a stronger
and independent predictor for future stroke than average
systolic BP and its value was similar in subjects treated or
not treated for hypertension. These findings were confirmed
in three cohorts with a history of ischemic stroke or
TIA selected from randomized clinical trials (European
Stroke Prevention Study, Dutch TIA and Anglo-Scandinavian
CardiacOutcomeTrial-Blood Pressure LoweringArm,ASCOT-
BPLA). In the UK-TIA patients, maximum systolic BP
predicted stroke independently of average systolic BP.
Patients who did not have sustained hypertension but
had episodic severe hypertension at one or more visits had
a higher risk of stroke as compared to those with persistent
hypertension, despite having lower average systolic BP. There
was no association between diastolic BP variability and the
risk of stroke.
In the ASCOT-BPLA trial, high-risk hypertensive subjects
were randomized to the treatment based on amlodipine adding
perindopril mg as required or atenolol adding thiazide diuretic.
The majority of patients (89 %) had no history of previous
stroke or transient ischemic attack. Compared with the
atenolol-based regimen, individuals on the amlodipine-based
regimen had a lower risk of fatal and non-fatal stroke (hazard
ratio 0.77, 95%CI 0.66-0.89, p =0.0003), total cardiovascular
events (hazard ratio 0.84, 95 % CI 0.78-0.90, p <0.0001), and
all-cause mortality (hazard ratio 0.89, 95 % CI 0.81-0.99,
p =0.025). Visit-to-visit BPV was a strong predictor of both
stroke and coronary events, while average systolic BP was a
weaker predictor of both [91].
In their study they also analyzed data from 18,530
patients from the ASCOT-BPLA study without a history of
cerebrovascular incident including subgroup of 1,905
participants with repeated ABPM [90]. BPV assessed using
ABPM, and expressed as the standard deviation of daytime
systolic BP, correlated with visit-to-visit office systolic BPV,
and both measures predicted independently of daytime average
systolic BP, in particular in younger patients and at lower values
of mean systolic BP. Visit-to-visit BPVwas a stronger predictor
for cardiovascular outcomes than variability on ABPM. Visit-
to-visit BPV was greater in the atenolol than in the amlodipine
group. In the subsequent meta-analysis they analyzed effects of
different classes of antihypertensive drugs on BPV variability
and the risk of stroke [92••] – see “Optimal selection for
antihypertensive drugs for stroke prevention”.
The prognostic importance of visit-to-visit BPV was
supported by data from the Third National Health and
Nutrition Examination Survey [93]. In a cohort representing
the USA population, total mortality was 50 % greater in
subjects with the highest tertile of BPV. Data on incidents of
stroke were not presented. The relationship between visit-to-
visit BPVwas also observed in subjects without hypertension.
Greater BPV was associated with age, female gender, history
of myocardial infarction, higher mean systolic BP and pulse
pressure, and use of ACE inhibitors. However, in the European
Lacidipine Study on Atherosclerosis (ELSA), which included
1,521 hypertensive patients observed for four years, long-term
BPVwas not related to the risk of cardiovascular complications
(separate number of strokes were not listed). On the contrary,
subclinical complications as well as cardiovascular outcomes
were significantly correlatedwith themean clinic or ambulatory
SBP [94].
Recently, Hastie et al. [95] published a study which
investigated data on the prognostic value of long-term BPV.
In a large population of 16,011 treated hypertensive patients
with a follow up extending up to 35 years, they found a
consistent association between increasing values of long-
term and ultra long-term BPV and risks of cardiovascular
and non-cardiovascular mortality, independent from average
systolic BP. In contrast to previous studies, no significant
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relationship was observed between BPVand stroke mortality.
However, previous studies that reported strong links between
BPV and stroke assessed stroke incidence, for which the
authors had no data. Also, in meta-analysis of 14 clinical trials,
greater BPV was not related to higher risk of new-onset atrial
fibrillation suggesting that other mechanisms might explain
the association between variability and stroke risk [96].
In some studies, measures of intra-individual variability on
a visit and not on individual visit-to-visit variability were used,
however strict correlation between these two measures of
BPV was demonstrated [90]. Using data from the UK-TIA
Aspirin Trial and the European Carotid Surgery Trial (ECST),
Howard and Rothwell show a reproducibility of repeated
BPV measurements in subjects with previous cerebrovascular
accidents [97]. This finding was also confirmed in the Cohort
Study ofMedication Adherence among older Adults (CoSMO)
which included 772 elderly with treated hypertension [98] and
by the data from the Glasgow Blood Pressure Clinic [95] with
mostly patients with uncomplicated hypertension.
Episodic hypertension and high visit-to-visit BPV despite
good control of mean BP indicates an increased stroke risk.
Optimal Blood Pressure for Prevention of Stroke
Early trials demonstrated that BP-lowering was effective in
preventing stroke in subjects with severe hypertension, in later
studies these benefits were also shown in patients with mild to
moderate hypertension. In the following clinical trials,
reduction in stroke was observed in various populations:
elderly, subjects with isolated systolic hypertension, different
ethnic groups, subjects with diabetes, high cardiovascular risk,
history of coronary heart disease or previous cerebrovascular
incident [99]. Results of meta-analysis which used data from
147 randomized clinical trials showed that blood pressure
reduction of 10 mm Hg systolic and 5 mm Hg diastolic was
associated with a 41 % (33 % to 48 %) reduction in stroke
for all trials, 46 % (35 – 55 %) in primary prevention trials,
44 % (21 – 44 %) in secondary prevention trials, and 35 %
(20 – 47 %) in trials including subjects with a history of
coronary heart disease. The reductions in disease events in the
trials were similar to those expected from the cohort study
[100••].
The risk of stroke increases continuously above BP values
of 115/75 mm Hg. In clinical trials average BP on treatment
usually did not fall below 130/80 mm Hg, but available data
show continuous reduction of stroke risk parallel to attained
BP level. Data from clinical trials do not suggest a J-curve
phenomenon between BP and the risk of stroke (see “Targeted
Blood Pressure and Stroke—J-curve Phenomenon?”) but there
are only a few clinical trials which investigated cardiovascular
outcomes in subjects treated to different BP goals (for review
see [101•].
The Action to Control Cardiovascular Risk In Diabetes –
Blood Pressure Arm (ACCORD-BP) study investigated
the effect of treatment aimed at intensive lowering of
SBP to <120 mmHg (compared to standard therapy) on the
incidence of cardiovascular events in 4,733 patients with type
2 diabetes [102]. After a year of treatment, the mean SBP
was 119.3 mmHg in the group managed intensively and
133.5 mmHg in the group on standard therapy, while the
mean DBP values were 64.4 and 70.5 mmHg, respectively.
The incidence of stroke was significantly lower in the group
receiving intensive treatment (0.32 % vs. 0.53 %; p =0.01); a
similar relationship was found for nonfatal stroke (0.30 %
vs. 0.47 %; p =0.03). However, the incidence of adverse
complications of treatment (orthostatic hypotension,
hyperkalemia, syncope, bradycardia, arrhythmia or renal
function impairment) was significantly increased (3.3 %
vs. 1.3 %). There was no significant difference in the primary
endpoint, comprising nonfatal MI or stroke, or death due to
cardiovascular causes (1.87 % per year in the group on
intensive treatment compared with 2.09 % of those on
standard therapy; p =0.20).
In the Studio Italiano Sugli Effetti CARDIOvascolari del
Controllo Della Pressione Arteriosa SIStolica (CARDIO-SIS)
study subject (n =1,111) with initial systolic BP >150 mm Hg
and no diabetes, were randomly allocated to strict control of
SBP (target value <130 mmHg; n =558), or the standard
one (target value <140 mmHg; n =553). After two years of
follow up, in the strict control group as compared to the typical
control, there was a significantly lower risk of total
cardiovascular events. There was also a difference in number
of incidents of stroke and TIA (1·6 % vs 0·7 %, standard and
intensive group, respectively), yet due to low numbers of
events they did not reach statistical significance [103].
Meta-analysis of 11 published randomized clinical
trials with 42,572 participants investigated the risk of
stroke in patients who achieved an intensive (<130 mm Hg)
or standard (<140 mm Hg) target of systolic BP. Tight BP
control appears to provide additional stroke protection
but only among patients with risk factors. Subjects with
established cardiovascular disease did not benefit from
lowering systolic BP<130 mm Hg [104].
Another meta-analysis compared different BP-lowering
agents and different BP intervention strategies on stroke
risk in a total of 73,913 patients with diabetes randomized
in 31 intervention trials [105]. Allocation to more-tight,
compared with less-tight, BP control reduced the risk of stroke
by 31 % (relative risk (RR) 0.61, 95 % confidence interval
(CI) 0.48-0.79], whereas the reduction in the risk of MI was
close to statistical significance [odds ratio (OR) 0.87, 95 % CI
0.74-1.02]. In a meta-regression analysis, the risk of stroke
decreased by 13 % (95 % CI 5-20, P =0.002) for each
5-mmHg reduction in SBP, and by 11.5 % (95 % CI 5-17,
P <0.001) for each 2-mmHg reduction in DBP. The risk of
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MI did not show any association with the extent of BP
reduction.
Current European Guidelines [98] recommend lowering of
BP below 140/90 mmHg for all subjects with hypertension with
few exceptions like diabetics (diastolic BP below 85 mm Hg)
and elderly over 80 years of age (systolic BP between
140- 150 mm Hg). Some data suggest that further lowering
of BP close to optimal level (120/80 mm Hg) may offer
additional protection against stroke. However, this strategy
can be considered only in subjects with uncomplicated
hypertension and initial high stroke risk.
Classes of Antihypertensive Drugs and Stroke Prevention
Starting from the 1980s, randomized trials have compared the
effects of different blood pressure lowering medication on
cardiovascular events. Meta-analysis of these trials did not
find any substantial differences between treatment regimens
and combined cardiovascular outcomes. Generally, the major
benefit, including protection against stroke, was attributed to
the treatment regimen offering lower BP level.
However, some data showing that in the case of primary
stroke prevention, calcium channel blockers may be more
effective than other groups of drugs. In the ASCOT-BPLA
study, a treatment regimen based on amlodipine was more
effective in stroke reduction than treatment based on atenolol.
However, there was a slightly lower blood pressure achieved
in the amlodipine arm than in the atenolol arm, and it may be
responsible for observed differences in stroke risk [91]. The
reduced risk of stroke in patients treated with a calcium
channel antagonist as compared with other classes of BP
lowering medications did not reach statistical significance in
other trials [100••].
Results of the ASCOT-BPLA trial opened a debate on the
role of beta-blockers in the treatment of uncomplicated
hypertension. Some group of experts recommended avoiding
use of beta-blockers as first line treatment due to their lower
protection against stroke [106]. Meta-analysis by Law et al.
[100••] included all identified randomized trials of BP
lowering drugs in which coronary events or stroke were
recorded. The relative risk estimates for stroke in the drug
comparison trials were close to 1.0, with two exceptions:
greater preventive effect of calcium channel blockers than
other drugs (relative risk 0.91, 95 % confidence interval
0.84 - 0.98; p =0.01), and a lesser effect ofβ blockers (relative
risk 1.18, 1.03 - 1.36; p =0.02). The differences remained
significant after adjustment for the small difference in blood
pressure reduction between the groups. The observed
lesser effect of β blockers, however, was based on trials that
directly compared calcium channel blockers with β blockers.
Exclusion of the results of these trials from meta-analysis
weakened the evidence favoring a disadvantage of β blockers
over the three other classes (relative risk 1.11, 0.86 - 1.44;
p =0.40) but had little effect on the strength of evidence
favoring an advantage of calcium channel blockers over the
three other classes of drug (relative risk 0.93, 0.86 to 1.01;
p =0.07). The results of comparisons of different classes of
antihypertensive drugs were similar in primary and secondary
prevention of stroke.
Beta-blockers and calcium channel antagonists differ in
their influence on central BP measured in the aorta. The
Conduit Artery Function Evaluation (CAFÉ) substudy of
ASCOT BPLA showed greater reduction of central SBP as
compared to brachial BP in patients in the amlodipine arm
than in subjects on atenolol-based therapy [107]. For a similar
effect on brachial BP, amlodipine lowered central SBP by an
additional 4.3 mm Hg as compared to atenolol. The influence
on central aortic BP might explain the results of the Nordic
Diltiazem (NORDIL) trial where, despite lower systolic BP by
3 mm Hg, the number of fatal and nonfatal strokes was
significantly higher on beta-blocker than during administration
of calcium channel blocker (7.9 vs 6.4 events per 1000 patient-
years; p =0.04) [108]. Ding et al., performed a meta-analysis
including trials that compared beta-blockers with other classes
of anti-hypertensive agents in their effect on stroke and central
hemodynamics [109]. In nine trials, beta-blockers reduced
central aortic pressure (estimated as an Augmentation
Index, AI) to less extent than other classes of drugs. The
difference in central systolic BP could be largely explained
by the heart-rate slowing effect of beta-blockers. In a
subsequent meta-regression of these trials , the base-line
adjusted change in heart rate by ten beats per minute was
associated with a significant increase of AI by 7 %. In
outcome trials, odds ratio for stroke was 1.23, which
corresponds to the difference in central SBP derived from
the above meta-regression analysis.
Calcium channel blockers lower BP acting on resistance
arterioles and in a small, but interesting study on stroke
outcome, survivors of acute stroke had a lower systemic
vascular resistance [110].
Differences between angiotensin-converting enzyme
inhibitors and angiotensin receptor blockers on the risk of
stroke were investigated in the meta-analysis including trials
in subjects with high cardiovascular risk (ONTARGET),
heart failure (ELITE), post-MI (OPTIMAAL, VALIANT) or
diabetic nephropathy (DETAIL). Although both groups of
drugs reduced BP to the same extent, and there was no
difference in the risk of cardiovascular mortality and MI,
the risk of stroke was slightly lower with ARBs than ACE
inhibitors (odds ratio 0.92; 95 % confidence interval
0.85-0.99; P =0.037) [111].
Major clinical trials with different classes of BP lowering
drugs in hypertensive populations without previous history of
cerebrovascular events (less 5 % of stroke victims at the
baseline) are listed in Table 1.
Curr Hypertens Rep (2013) 15:559–574 567
Visit-to-visit BP variability is a predictor for future stroke
and in the ASCOT BPLA trial this parameter was greater in
the atenolol than in the amlodipine group [91]. Webb et al.,
using data from 389 trials analyzed the effect of different
classes of antihypertensive drugs on BPV [92••]. Compared
with other drugs, interindividual variation in SBP was reduced
Table 1 Major clinical trials with different classes of BP lowering drugs in hypertensive population without previous history of cerebrovascular events
(less 5 % of stroke victims at the baseline)
Trial
[ref]
No of participants Mean age (yrs) Main drug /
comparator





systolic diastolic treatment Control/
comparator
ABCD-2[117] 237 243 59 iACE/CcCB 7.4 6.0 4 13
ADVANCE [118] 5569 5571 66 any 5.6 2.2 215 218
Australian TTMH [119] 1721 1706 50 D/plac - 5.6 13 22
BBB [120] 1063 1063 60 any 8.7 7.1 8 11
CAPPP [121] 5492 5493 52 iACE/plac - - 193 149
CONVINCE [81] 8241 8361 66 CaCB/bB+D 0.1 0.7 133 118
DREAM [122] 2623 2646 55 iACE/plac 4.3 2.7 4 8
EWPHE [123] 381 396 72 D/plac 21 8 27 39
FEVER [124] 4841 4870 62 CaCB/plac 4.2 2.1 177 251
HEP [125] 408 459 69 D+bB/plac 11 18 18 38
HDFP [126–128] 5349 5317 51 D/plac - 5.3 87 142
HOT [129] 12526 6464 62 any 2.8 3.0 200 94
Hunan province [130] 1040 1040 52 CaCB/plac 8.8 5.6 37 79
HYVET pilot [131] 426 426 84 D/plac 22 11 6 18
431 84 iACE/plac 23 11 12 -
HYVET [48] 1933 1912 84 D/plac 15 6.1 51 69
LIFE [132] 4605 4588 66 ARB/bB 1.1 -0.2 232 309
MRC-1[133] 4297 8654 52 D/plac 13.2 6.1 18 109
4403 52 bB/plac 9.5 4.9 42 -
MRC-2 [134] 1081 2213 70 D/plac 16.4 7.0 45 134
1102 70 bB/plac 14.1 7.3 56 -
NORDIL [108] 2786 2805 60 CaCB/D+bB 3.1 0.2 200 236
Oslo [135] 406 379 45 D/plac 16.7 9.8 0 5
PREVENDIT [136] 431 433 51 iACE/plac 3.8 2.9 1 10
SHEP pilot [137] 443 108 72 D/plac 15 4 11 6
SHEP [138] 2306 2331 72 D/plac 13.0 4.3 97 155
STOP [139] 781 780 76 D+bB 8.1 19.5 28 49
STOP - 2 [140] 2213 2196 76 D+bB/CaCB 1 0 86 83
2213 2205 D+bB/iACE 1 0 86 86
Syst-Eur [141] 2398 2297 70 CaCB/plac 10 4.5 47 77
Syst-China [142] 1253 1141 67 CaCB/plac 8.3 3.1 45 59
TOMHS [143] 668 234 55 any 6.8 3.7 - -
UKPDS 38 [144, 145] 758 390 56 any 10 4 17 34
UKPDS 39 [145] 400 358 56 iACE/bB 11 6 21
USPHS [146] 193 196 44 D+Res/plac 9.8 18.0 1 6
VA-1[147] 73 70 51 D+Res+Hdr/plac 27 38 1 3
VA-2 [148] 186 194 51 D+Res+Hdr/plac 18.6 31.3 5 20
VANHLBI [149] 508 504 38 D - 5.9 0 0
D- thiazide, bB - β blocker, iACE - ACE inhibitor, ARB – angiotensin II receptor antagonist, CaCB - calcium-channel blocker, Res- rauwolfia, Hdr –
hydralazine, plac - placebo
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by calcium-channel blockers and non-loop diuretic drugs, and
increased by ACE inhibitors, ARBs and beta-blockers.
Compared with placebo only, interindividual variation in
SBP was reduced the most by calcium-channel blockers. In
another study, they analyzed within-individual visit-to-visit
variability using data from two trials: ASCOT BPLA
comparing atenolol and amlodipine-based regimens and the
Medical Research Council (MRC) comparing atenolol-based
with diuretic-based BP lowering therapy [112]. In patients
during the MRC study, BPV increased on beta-blocker
treatment comparing to placebo and diuretic. Subsequent
temporal trends in variability in blood pressure during follow
up in the atenolol group correlated with trends in stroke risk.
In ASCOT BPLA, variability decreased over time in the
amlodipine group and increased in the atenolol group. The
authors conclude that the opposite effects of calcium-channel
blockers and beta-blockers on variability of blood pressure
account for the disparity in observed effects on risk of
stroke and expected effects based on mean blood pressure.
The effects of calcium channel blockers on BPV persisted
when they were used in combination with other agents
[113].
However, in the above mentioned studies atenolol
was given once daily despite its relatively short half-
life of 6-7 hours. Limited duration of BP lowering
effect of atenolol could cause episodic hypertension
and increased BPV. Comparison of different beta-
blockers showed that beta1-selective is associated with
lower BPV than are the non-selective beta-blockers.
Among vasodilating beta-blockers, carvedilol (non-
selective) increases BPV, while nebivolol (selective)
does not affect BPV [114].
The reduction in BPV was also associated with the
frequency of headaches. In a systematic review of randomized
trials it was demonstrated that antihypertensive treatment
reduced the incidence of headache compared to placebo, but
there were significant differences in the magnitude of the
effect, independent of reduction in systolic BP [115]. Beta-
blockers reduced headache more than other classes and
calcium channel blockers did not reduce headache compared
to placebo and increased it compared to other drug classes.
The mechanism underlying these findings and their clinical
significance is unknown.
According to the studies on BPVand stroke prevention, an
ideal antihypertensive drug should reduce both mean blood
pressure and variability.
Conclusions
Hypertension is the most important modifiable risk factor
for stroke and according to the WHO Global Report, 54 %
of cerebrovascular incidents are attributable to high BP
(SBP>115 mm Hg) with half of them related to sustained
hypertension (>140/90 mm Hg). The association between BP
and the stroke risk is continuous without any evidence of a
threshold down to at least 115/75 mm Hg. Hypertension
increases the risk for both ischemic and hemorrhagic
stroke, both in subjects without or with the history of
coronary heart disease or previous stroke. ABPM is not only
a better predictor of stroke risk than office BP, but also can
identify disturbances in diurnal variation of BP. Absence of
nocturnal drop (“nondipping”) or excessive fall of nighttime
BP (extreme dippers), early morning acceleration in BP
after leaving the bed (“morning surge”) are especially
associated with cerebrovascular disease. Only ABPM or
HBPM can detect two forms of hypertension: - “white coat”
and “masked” hypertension – and both carry an increased risk
of cardiovascular complications, including stroke.
Increased variability in BP is a risk factor of stroke
independent of means BP. In a series of secondary analysis
of data from clinical trials, Webb and Rothell reported a
significant association between BPVand efficacy of different
classes of antihypertensive medications in primary and
secondary stroke prevention. However, their data are
disputable since they extrapolated data from between patients
BP variability, as a measure of within patient BP variability.
It is suggested that lower efficacy of beta-blockers for
stroke protection may result from their inferior effect on
BPV and central aortic pressure; however, most of the data
comes from the studies with atenolol, dosed in a manner not
offering a smooth and long lasting lowering of BP. There are
many unresolved issues regarding optimal stroke protection.
The issue of J-curve and goal BP in primary and secondary
prevention is still debated, and data from clinical trials are
very limited. However, recent data from the Reasons for
Geographic and Racial Differences in Stroke (REGARDS)
observational study, which included 13,948 patients, generate
a hypothesis that for all patients older than 55 years of
age, the recommended level of systolic blood pressure
should be less than 140 mm Hg, with optimal values
possibly between 120 and 139 mm Hg [116]. According to
the current state of knowledge, in patients without coronary
heart disease, it seems we are justified in loweingr BP even
below 130/80 mm Hg, yet this is not recommended in current
guidelines. Also, there is no clear indication to guide our
treatment based on BP variability or disturbances of diurnal
BP rhythm.
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